{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive+Metastatic+Breast+Cancer&page=2", "query": { "condition": "Hormone Receptor Positive Metastatic Breast Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive+Metastatic+Breast+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T11:20:56.593Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06745804", "title": "Study of 68Ga-R10602", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locoregionally Recurrent Hormone-receptor Positive Breast Cancer", "Metastatic Hormone Receptor Positive Breast Cancer", "Hormone Receptor Positive Breast Adenocarcinoma" ], "interventions": [ { "name": "68Ga-R10602 injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radionetics Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-12-10", "completion_date": "2026-05-04", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-07-24T11:20:56.593Z", "location_count": 6, "location_summary": "Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06745804" }, { "nct_id": "NCT02069093", "title": "Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "Dexamethasone based mouthwash", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 92, "start_date": "2014-05", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2017-02-13", "last_synced_at": "2026-07-24T11:20:56.593Z", "location_count": 23, "location_summary": "Fayetteville, Arkansas • Anaheim, California • Los Angeles, California + 17 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02069093" }, { "nct_id": "NCT06388122", "title": "DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HER2-negative Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Metastatic Breast Cancer", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "HER2 Negative Breast Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Metastatic Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2024-04-30", "completion_date": "2031-06-15", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-07-24T11:20:56.593Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06388122" }, { "nct_id": "NCT06760637", "title": "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PF-07220060", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "abemaciclib", "type": "DRUG" }, { "name": "palbociclib", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1035, "start_date": "2025-01-06", "completion_date": "2037-12-29", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-07-24T11:20:56.593Z", "location_count": 218, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06760637" }, { "nct_id": "NCT02107703", "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 669, "start_date": "2014-07-22", "completion_date": "2027-12", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-07-24T11:20:56.593Z", "location_count": 43, "location_summary": "Jonesboro, Arkansas • Springdale, Arkansas • La Jolla, California + 36 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02107703" }, { "nct_id": "NCT01823835", "title": "A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GDC-0810", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 152, "start_date": "2014-12-29", "completion_date": "2020-03-13", "has_results": true, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-07-24T11:20:56.593Z", "location_count": 8, "location_summary": "San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01823835" }, { "nct_id": "NCT06086340", "title": "Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 779, "start_date": "2023-09-29", "completion_date": "2024-01-24", "has_results": true, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-07-24T11:20:56.593Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06086340" }, { "nct_id": "NCT00759642", "title": "Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2009-03", "completion_date": "2018-08-20", "has_results": true, "last_update_posted_date": "2019-07-01", "last_synced_at": "2026-07-24T11:20:56.593Z", "location_count": 3, "location_summary": "Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00759642" }, { "nct_id": "NCT06525766", "title": "Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen-receptor-positive Breast Cancer", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-10-01", "completion_date": "2030-10-15", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-07-24T11:20:56.593Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06525766" }, { "nct_id": "NCT00101062", "title": "Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2004-01", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-07-24T11:20:56.593Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101062" } ] }